FDA Grants Fast Track Status to Cancer Vaccine UV1 for Advanced Malignant Melanoma
Source: OncLive, Oct 2021
The FDA has granted a fast track designation to the universal cancer vaccine UV1 for use in combination with checkpoint inhibitors in patients with unresectable or metastatic melanoma, either as an add-on therapy to pembrolizumab (Keytruda) or to ipilimumab (Yervoy).1
